The event is taking place on Prague, Czech Republic, from 20 to 22 March 2017 and PCI Biotech will present a poster on 21 March ... includes a brief technology background, preclinical results ...

IO Biotech has deployed its unique approach to modulate TGFb1 activity in the TME, and the poster details the identification and characterization of highly selective TGFb1 peptide vaccines.

If anyone has information on the whereabouts of the TAK-279 poster, Fierce Biotech is standing by to collect tips. We intend to work tirelessly—at least until the next news cycle, anyway—to ...

Two of the posters will include new in vivo and in vitro data related to IO Biotech’s lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study.

The poster will be available on the “Posters & Publications” page of the IO Biotech website at the start of the meeting. About IO102-IO103 IO102-IO103 is an investigational immune-modulating ...

(“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today ...

PanGIA Biotech, a company advancing urine-based ... biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted ...

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place ...

The second abstract accepted for poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1. Times: Poster hall ...

Morningstar brands and products Company Portfolio ...